ISRCTN90906759进行中（未招募）2 期
A phase II/III study to determine the efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 12,390
研究概览
简要总结
2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33220855/ results (added 19/11/2020) 2021 Interim results article in https://doi.org/10.1016/S0140-6736(20)32661-1 interim results (added 09/12/2020) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33617777/ results (added 23/02/2021) 2021 Interim results article in https://pubmed.ncbi.nlm.nih.gov/34480858/ Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK (added 06/09/2021) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35779491/ (added 04/07/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 04/12/2020 (see additional files for previous interventions):
- •1. Adults aged 18-55 years (groups 4, 5, 6 and 11)
- •2. Adults aged 56-69 years (groups 1, 7 and 9)
- •3. Adults aged 70 years and older (groups 2, 8 and 10)
- •4. Able and willing (in the Investigator’s opinion) to comply with all study requirements
- •5. Willing to allow the investigators to discuss the volunteer’s medical history with their General Practitioner and access all medical records when relevant to study procedures
- •6. For females of childbearing potential only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination
- •7. Agreement to refrain from blood donation during the course of the study
- •8. Provide written informed consent
- •Additional Inclusion criteria for Group 12 (HIV sub-study):
- •1. HIV positive
- •2. Receiving antiretroviral therapy
- •3. Undetectable HIV viral load
- •4. CD4 >350 cells/ml
排除标准
- •Current exclusion criteria as of 21/10/2020 (see additional files for previous interventions):
- •1. Participation in COVID-19 prophylactic drug trials for the duration of the study
- •Note: Participation in COVID-19 treatment trials is allowed in the event of hospitalisation due to COVID-19. The COV002 study team should be informed as soon as possible
- •2. Participation in SARS-CoV-2 serological surveys where participants are informed of their serostatus for the duration of the study
- •Note: Disclosure of serostatus post enrolment may accidently unblind participants to group allocation. Participation in COV002 can only be allowed if volunteers are kept blinded to their serology results from local/national serological surveys
- •3. Receipt of any vaccine (licensed or investigational) other than the study intervention within 30 days before and after each study vaccination, with the exception of the licensed seasonal influenza vaccination and the licensed pneumococcal vaccination. Participants will be encouraged to receive these vaccinations at least 7 days before or after their study vaccine
- •4. Prior or planned receipt of an investigational or licensed vaccine or product likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus vaccines). This exclusion criteria will not apply to group 11, as recruitment will be targeted at those volunteers who previously received a ChAdOx1 vectored vaccine.
- •5. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
- •6. Any confirmed or suspected immunosuppressive or immunodeficient state (except group 12, where HIV infected participants are allowed); asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting =14 days)
- •7. History of allergic disease or reactions likely to be exacerbated by any component of ChAdOx1 nCoV-19 or MenACWY
- •8. Any history of angioedema
- •9. Any history of anaphylaxis
- •10. Pregnancy, lactation or willingness/intention to become pregnant during the study
- •11. Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
- •12. History of serious psychiatric condition likely to affect participation in the study
- •13. Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture
- •14: Continuous use of anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban)
- •15. Suspected or known current alcohol or drug dependency
- •16. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
- •17. Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well-controlled comorbidities are allowed)
- •18. History of laboratory-confirmed COVID-19 (except groups 5d, 9, 10 and 11).
- •18.1 Seropositivity to SARS-CoV-2 before enrolment (except groups 5d, 9 and,10 and 11)
- •Additional exclusion criteria for
研究者
相似试验
进行中（未招募）
1 期
A phase I/II study to determine efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteersCOVID-19 (SARS-CoV-2 infection)Infections and InfestationsISRCTN15281137niversity of Oxford1,077
已完成
2 期
A study of the drugs AZD2014 and rituximab in relapsed or refractory diffuse large B-cell lymphomaTopic: CancerSubtopic: LymphomaDisease: Lymphoma (other)CancerISRCTN10760016niversity of Birmingham36
已完成
1 期
Efficacy and safety of olaparib in relapsed and refractory chronic lymphocytic leukaemia patients with an 11q deletion or ATM mutation and relapsed/refractory patients with T-prolymphocytic leukaemia and mantle cell lymphomaChronic lymphocytic leukaemiaLymphoid leukaemiaCancerISRCTN34386131niversity of Birmingham (UK)15
已完成
2 期
Phase II/III Study to Evaluate the Efficacy and Safety of Chaperone Therapy with Ambroxol Hydrochloride (JT408T) in Patients with Neuronopathic Gaucher disease (Japan- Lysosomal Optimization Study: J-LO study)euronopathic Gaucher diseaseJPRN-jRCT2091220421Tottori University Hospital, Departrment of Child Neurology6
进行中（未招募）
不适用
A phase II-III trial assessing the efficacy and safety of three doses of the ALK HDM tablet in house dust mite allergic subjects. - NDsubjects suffering from house dust mite allergyMedDRA version: 8.1Level: LLTClassification code 10057631Term: House dust allergyEUCTR2006-001795-20-ITALK-ABELLO800